December 18, 2017
The efficacy of many FDA-approved cancer drug combinations is not due to synergistic interactions between drugs, but rather to a form of “bet hedging,” according to a new study published by Harvard Medical School researchers in Cell. Reanalyzing data from 15 clinical trials, the researchers show that independent action—in which drugs […]
